| __timestamp | Axsome Therapeutics, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 305409000 |
| Thursday, January 1, 2015 | 2419289 | 377080000 |
| Friday, January 1, 2016 | 6343648 | 432829000 |
| Sunday, January 1, 2017 | 7206691 | 496079000 |
| Monday, January 1, 2018 | 9351522 | 557616000 |
| Tuesday, January 1, 2019 | 13598030 | 658498000 |
| Wednesday, January 1, 2020 | 28896749 | 770456000 |
| Friday, January 1, 2021 | 66646205 | 840100000 |
| Saturday, January 1, 2022 | 159253661 | 944700000 |
| Sunday, January 1, 2023 | 323123000 | 1136600000 |
| Monday, January 1, 2024 | 411359000 | 1464300000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Vertex Pharmaceuticals Incorporated and Axsome Therapeutics, Inc. have shown contrasting approaches to SG&A cost management. From 2014 to 2023, Vertex's SG&A expenses have consistently increased, peaking at approximately $1.14 billion in 2023, reflecting a steady growth trend. In contrast, Axsome's SG&A expenses, while significantly lower, have surged by over 23,000% from 2014 to 2023, reaching around $323 million. This dramatic increase highlights Axsome's aggressive expansion strategy. Despite the disparity in absolute numbers, Axsome's rapid growth in SG&A expenses suggests a strategic investment in scaling operations. Meanwhile, Vertex's larger but more stable SG&A growth indicates a mature, well-established market presence. Understanding these trends provides valuable insights into each company's operational strategies and market positioning.
Selling, General, and Administrative Costs: AstraZeneca PLC vs Vertex Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Pfizer Inc. vs Axsome Therapeutics, Inc.
Bristol-Myers Squibb Company or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Vertex Pharmaceuticals Incorporated or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation